Skip to content

Multi center study on the permeation mechanism of in vitro transdermal drug delivery based on the application of OFM and AI technology in vitro skin

Multi center study on the permeation mechanism of in vitro transdermal drug delivery based on the application of OFM and AI technology in vitro skin

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112015
Enrollment
Unknown
Registered
2025-11-10
Start date
2025-11-14
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scar prevention/repair

Interventions

Open micro irrigation OFM technology:None
Franz diffusion pool method:None

Sponsors

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Male and female participants aged 18 to 65 years old (including 18 and 65 years old); 2. Accept plastic surgery, during which excess skin tissue must be removed, and the area of normal skin tissue removed in the same region must be >= 100cm^2; 3. Those who are able to communicate well with researchers, fully understand the purpose and requirements of this trial, voluntarily participate in clinical trials, and sign a written informed consent form for biological sample collection.

Exclusion criteria

Exclusion criteria: 1.Open wounds or redness, irritation, or damage to the skin; 2.The skin color is significantly different, which affects the evaluation of the skin (such as the presence of scar tissue exceeding 10% of the excised skin, tattoos, abnormal skin color, texture, etc.); 3. Previous skin diseases, such as atopic dermatitis, psoriasis, vitiligo, or diseases known to change skin appearance or physiological reaction (such as diabetes, porphyria); 4. Referring to the four preoperative examinations of our hospital, syphilis (TP), five hepatitis B, hepatitis C (HCV), and human immunodeficiency virus (HIV), any of which is clinically significant; 5. Before screening, drugs or patches that have an impact on the skin cannot be identified as completely metabolized; 6. The researcher determines that they are not suitable to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
Maximum permeation rate;

Secondary

MeasureTime frame
Analysis of Infiltration Promotion Mechanism;

Countries

China

Contacts

Public ContactYixin Zhang

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

zhangyixin6688@163.com+86 21 2327 1699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026